Skip to content
Open access

LDL-C–stratified residual lipoprotein(a) and inflammatory risk after acute myocardial infarction among patients with prior statin use

Aug 2026 · BMC Medicine · 0 citations

TL;DR

In patients with AMI despite documented prior statin exposure, the prognostic associations of residual inflammatory and Lp(a) risk appeared to differ across admission LDL-C strata, supporting the potential value of LDL-C–stratified residual risk assessment.

Abstract

Patients can experience acute myocardial infarction (AMI) despite documented prior statin exposure, indicating persistent residual cardiovascular risk. The prognostic relevance of lipoprotein(a) [Lp(a)] and residual inflammation in this setting remains unclear. This retrospective multicentre cohort study included 6,498 adults hospitalized for AMI with prior statin use. Baseline low-density lipoprotein cholesterol (LDL-C) at admission was used to stratify patients into low (< 2.6 mmol/L) and high (≥ 2.6 mmol/L) LDL-C groups. Residual risk profiles were defined by elevated Lp(a) (> 30 mg/dL), elevated high-sensitivity C-reactive protein (hs-CRP > 3 mg/L), or both. The primary outcomes were major adverse cardiovascular events (MACE) and all-cause death. Baseline characteristics differed across residual LDL-C strata and risk profiles. During a median follow-up of 5.71 years (IQR 4.38–7.27), restricted cubic spline analyses showed a significant association between Lp(a) and outcomes only in the low LDL-C group, whereby high residual inflammatory risk (adjusted hazard ratio [aHR] 1.53, 95% CI 1.24–1.88), high residual Lp(a) risk (aHR 1.44, 95% CI 1.11–1.87), and combined residual risk (aHR 1.47, 95% CI 1.16–1.86) were each associated with higher MACE risk. In the high LDL-C group, no significant residual risk category was associated with MACE. Irrespective of LDL-C status, residual inflammatory risk alone and combined residual risk were associated with increased risks of all-cause mortality and cardiovascular death. Sensitivity analyses suggested that a 30 mg/dL Lp(a) cut-off may be more informative in this cohort. In patients with AMI despite documented prior statin exposure, the prognostic associations of residual inflammatory and Lp(a) risk appeared to differ across admission LDL-C strata, supporting the potential value of LDL-C–stratified residual risk assessment.

Read PDF

Similar papers

Open access Sep 2026

Prognostic value of combined LDL-C and remnant cholesterol stratification for 24-month major adverse cardiovascular events after primary PCI in patients with STEMI

Elevated RC, rather than isolated high LDL-C, is associated with adverse outcomes, which may help identify patients with residual lipid-related risk, which may help identify patients with residual lipid-related risk in STEMI patients after primary PCI.

Qian-Ying Xie, Chao-Yi Wang, Wen-Jing Zhao et al. · 0 citations
Open access Sep 2026

Early Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study.

Achievement of LDL-C <55 mg/dL within 6 months after AMI is independently associated with a meaningful reduction in recurrent ASCVD events in real-world practice, and the temporal mismatch between early post-discharge risk and delayed lipid assessment underscores the need for proactive, multidisciplinary care models to...

Henry C. Okoroike, Wei-Li Zheng, Faisal Hasan et al. · 0 citations
Aug 2026

Impact of Low-density Lipoprotein Cholesterol Levels on Cardiovascular Risk in Chronic Kidney Disease: A Stage-specific Analysis.

High LDL-C levels were associated with increased cardiovascular risk in patients with chronic kidney disease but not in patients with end-stage kidney disease after multivariable adjustment, suggesting stage-specific LDL-C targets are needed to optimize cardiovascular risk management in chronic kidney disease.

N. Heo, Kyungdo Han, Kyu-Na Lee et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.